Fig. 8

STYK1-driving peptides efficiently inhibit pancreatic cancer development. a–d Transwell migration/invasion assays in BxPC-3 and PANC-1 cells treated with control or CP-SkP peptides (n = 3), including representative images and quantification. Scale bar: 100 μm. e Schematic of intraperitoneal peptide administration in nude mouse xenograft models. f Excised tumor images from peptide-treated groups. g Excised tumor weights. h Tumor growth kinetics in peptide-treated mice (n = 4). i H&E and IHC staining (Ki67/Axin2/CyclinD1/p62) in tumor tissues. Scale bar: 100 μm. j Schematic of intraperitoneal peptide administration in KPC mice. k Overall survival rates of KPC mice treated with control (n = 9), CP-SkP2 (n = 8), and CP-SkP5 (n = 8) peptides. l Representative images of the pancreas in the groups treated with control, CP-SkP2, and CP-SkP5 peptides. Scale bar: 40 μm. m, n Representative histological images and the quantification of H&E staining in the indicating groups (n = 3). Scale bar: 40 μm. o The quantification of sirius red or alcian blue staining in the indicating groups (n = 3). p–u The serum concentration of BUN, ALT, AST, WBC, RBC, and PCT in mice treated with control, CP-SkP2, and CP-SkP5 peptides (n = 3). v Representative H&E images of normal organs including lungs, livers, and kidneys were collected from mice treated with control, CP-SkP2, and CP-SkP5 peptides. Scale bar: 40 μm. Data were represented as mean ± SD, *p < 0.05; **p < 0.01; ***p < 0.001